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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S46accounted for by differences in DNA methylation of the +37 CpG site
that could inﬂuence the penetrance of rs143383 in susceptibility to OA
and in other common musculoskeletal diseases.
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ALLELIC EXPRESSION ANALYSIS IN PATIENT TISSUES OF THE
OSTEOARTHRITIS AND OF THE LUMBAR DISC HERNIATION
SUSCEPTIBILITY LOCI THAT MAP TO COL11A1
A.W. Dodd, E.V. Raine, L.N. Reynard, J. Loughlin. Newcastle Univ.,
Newcastle upon Tyne, United kingdom
Purpose: The arcOGEN genome-wide association scan (GWAS) has
generated evidence of association to OA of single nucleotide poly-
morphism (SNP) rs2615977 fromwithin intron 31 of COL11A1. This gene
codes for the a1 polypeptide chain of type XI collagen and has long been
considered a strong candidate for OA susceptibility, based on the
important structural role of type XI collagen in the cartilage extracel-
lular matrix and on the observation that penetrant mutations of
COL11A1 can cause Stickler's syndrome, which is a rare disease char-
acterized by severe early-onset secondary OA. Furthermore, a common
exonic SNP of COL11A1, rs1676486, has been reported to be associated
with lumbar disc herniation (LDH) in a Japanese population. LDH, like
OA, is a degenerative musculoskeletal condition whose prevalence
increases with age. Unlike rare diseases, many common complex traits
are mediated by cis-acting regulatory polymorphisms that inﬂuence
gene transcription or transcript stability, resulting in allelic expression
imbalance. The LDH SNP rs1676486 is an example of such a poly-
morphism, with the LDH-associated T allele of the SNP mediating
decreased stability of the COL11A1 transcript relative to the C allele. In
this study we therefore set out to assess: 1) whether the OA association
to rs2615977 was marking allelic expression imbalance of COL11A1 and
2) whether the detrimental effect that rs1676486 has on COL11A1
transcript expression in LDH is also observed in the cartilage of OA
patients.
Methods: Using RNA extracted from the cartilage of OA patients who
had undergone elective joint replacement surgery, we assessed
whether either SNP correlated with COL11A1 allelic expression by: 1)
measuring COL11A1 expression by quantitative PCR and then strati-
fying the data by genotype at each SNP in turn and 2) accurately
discriminating and quantifying the mRNA synthesized from both
alleles of each SNP, using allelic-quantitative PCR performed on
heterozygous patients. We studied a total of 73 male and female
patients, who had undergone either a hip or a knee replacement.
Linear regression was used to assess whether COL11A1 expression
relative to genotype differed signiﬁcantly from the null, whilst a 2-
tailed Mann-Whitney exact test was used to assess the signiﬁcance of
any allelic differences.
Results: We found no evidence for a correlation between COL11A1
expression levels and genotype at either SNP, nor were there any
correlations when the patients were stratiﬁed by the joint replaced
(all P-values were greater than 0.05). This stratiﬁcation analysis is
vulnerable to the natural variability in gene expression between
individuals, which can decrease its sensitivity and accuracy. For
example, in individuals of the same genotype we observed up to
a 250-fold difference in COL11A1 expression. The direct measurement
of allelic output is not vulnerable to such effects. In our allelic
expression analysis we found no evidence that genotype at the OA
associated SNP rs2615977 correlated with allelic expression imbal-
ance. However, we detected a complete correlation between allelic
expression imbalance and genotype at the LDH associated SNP
rs1676486: in all of the patients that we studied who were hetero-
zygous for this SNP the LDH associated T allele produced signiﬁcantly
less transcript than the C allele, with an average allelic ratio of 0.36
and P-value less than 0.0001. When we tested this SNP for association
in the arcOGEN GWAS of 7,410 cases and 11,009 controls, we did not
however detect any compelling evidence of association to OA (all
P-values were greater than 0.01).
Conclusions: In the tissues that we have studied our data does not
support the OA association signal at COL11A1, which is marked by SNP
rs2615977, as mediating an effect on the expression of the COL11A1
mRNA. However, the LDH SNP rs1676486 does mediate an effect on
COL11A1 expression in the same direction as that seen in LDH, but this
is not a risk factor for OA. Overall, COL11A1 can tolerate polymorphism
in its expression in hip or knee cartilage without this acting as a risk
factor for OA, something not seen in LDH.77
A GENETIC ANALYSIS OF OSTEOARTHRITIS OF THE KNEE IN NORTH
AMERICAN CAUCASIANS: RESULTS FROM THE OSTEOARTHRITIS
INITIATIVE AND JOHNSTON COUNTY OSTEOARTHRITIS PROJECT
L.M. Yerges-Armstrong 1, C. Lu 1, M.C. Hochberg 1, B. Mitchell 1,
J.M. Jordan 2, J.B. Renner 2, T. McSherry 3, D.M. Taverna 3,
D. Duggan 3, W.J. Mysiw 4, R. Jackson 4. 1Univ. of Maryland, Baltimore,
MD, USA; 2Univ. of North Carolina, Chapel Hill, NC, USA; 3 TGen,
Pheonix, AZ, USA; 4 The Ohio State Univ., Columbus, OH, USA
Purpose: A strong genetic contribution to osteoarthritis (OA) is widely
recognized although few loci have yet to be robustly associated with
knee OA susceptibility. To identify genes associated with knee OA, we
performed joint analyses across two large North American cohorts with
well-characterized phenotypes of knee OA: the Genetic Components of
Knee OA (GeCKO) Study, an ancillary study from the Osteoarthritis
Initiative (OAI), and the Johnston County (JoCo) Osteoarthritis Project.
Our goals were to 1) attempt replication of 14 single nucleotide poly-
morphisms (SNPs) previously reported in the literature to be associated
with hip or knee OA, and 2) conduct an agnostic genome-wide asso-
ciation (GWA) analysis.
Methods: Cases had at least one knee with deﬁnite radiographic OA,
deﬁned as the presence of deﬁnite osteophytes (OARSI grade 1)
regardless of the presence of joint space narrowing (equivalent to
Kellgren-Lawrence [KL] grade >2). Controls were required to be free of
radiographic evidence of OA in both knees (i.e., no evidence of both
osteophytes and joint space narrowing, or KL grade¼ 0). Based on these
deﬁnitions, there were 1,920 and 761 Caucasian cases in the GeCKO-OAI
and JoCo cohorts, and 885 and 634 controls, respectively, included in
the analyses. The 14 SNPs selected for replication were identiﬁed
through a review of candidate gene and GWA studies in the literature.
Genotyping was carried out on the Illumina 2.5M and 1M arrays in
GeCKO-OAI and JoCo, respectively. Association analyses were carried
out separately in each cohort with adjustments for age and sex.
Results: None of the 14 previously reported genetic variants for OA
achieved even nominal signiﬁcance (p<0.05) with knee OA in the
GeCKO-OAI sample, despite a power to detect odds ratios of 1.17 or
greater. A hypothesis-free GWA analysis was then carried out in the
GeCKO-OAI sample on the 1.3M SNPs that passed genotype cleaning
ﬁlters. No SNPs were associated with knee OA at GWA levels of statis-
tical signiﬁcance (P < 5x10-8). However, a total of 155 SNPs, repre-
senting 54 different chromosome regions, were suggestively associated
with knee OA at a threshold of P < 10-4. We then tested these SNPs for
association with knee OA in cases and controls from the JoCo Study. Of
the 87 SNPs available for replication in JoCo, none were signiﬁcantly
associated with knee OA at a nominal P < 0.01. At our tested levels of
signiﬁcance (i.e., P < 10-4 in GeCKO-OAI and P < 0.01 in JoCo), we
estimated that our sample would have 80% power to detect SNPs having
odds ratios of 1.34 or higher among all SNPs tested in GeCKO-OAI and
for the subset of SNPs tested for replication in JoCo for disease allele
frequencies of 0.20 or greater.
Conclusions: Our ﬁndings support the polygenic nature of the genetic
contribution to knee OA and the likelihood that contributing loci are
likely to have very small effects. While it is potentially challenging to
harmonize OA case and control deﬁnitions between different studies,
ongoing meta-analyses may best be able to accommodate the complex
genetic architecture of OA.
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THE IDENTIFICATION OF TRANS-ACTING FACTORS THAT
DIFFERENTIALLY REGULATE THE EXPRESSION OF GDF5 VIA THE
OSTEOARTHRITIS ASSOCIATED SNP RS143383
C.M. Syddall, L.N. Reynard, D.A. Young, J. Loughlin. Newcastle Univ.,
Newcastle upon Tyne, United Kingdom
Purpose: A single nucleotide polymorphism (SNP), rs143383, in the
growth and differentiation factor 5 (GDF5) gene has been widely
studied, with the T-allele of the SNP being associated with an increased
risk of osteoarthritis (OA) and of a number of other common muscu-
loskeletal diseases. The effect of the SNP on gene function has been
investigated with the T-allele producing less GDF5 transcript in
comparison with the C-allele, both in-vitro and in-vivo, a phenomenon
known as allelic expression imbalance (AEI). The aim of this study was
to identify the trans-acting regulatory factors responsible for this
rs143383-mediated GDF5 AEI.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S47Methods: An oligonucleotide pull-down assay followed by isobaric
mass tag labeling and tandem mass spectrometry was used to isolate
and quantify the proteins binding to each rs143383 allele. Further trans-
acting factors were identiﬁed using TransFac, Promo 3.0 and TESS
prediction software databases, followed by electrophoretic mobility
shift assays (EMSAs). Candidate proteins were investigated further
using antibody supershifts, and their ability to modulate GDF5
expression assessed using RNA interference (RNAi). Luciferase reporter
assays were used to assess the impact of over-expressing candidate
proteins on the transcriptional activity of both rs143383 alleles. Chro-
matin Immunoprecipitation (ChIP) was used to conﬁrm the binding of
these factors to GDF5 in-vivo.
Results: Tandem mass spectrometry identiﬁed the transcriptional co-
activator p15 as binding more avidly to the T-allele of rs143383. Upon
p15 knockdown, overall GDF5 expression increased while the allelic
expression imbalance was attenuated. Furthermore, GDF5 was enriched
following ChIP with an anti-p15 antibody. By EMSA supershift, we
identiﬁed the more avid binding of transcription factors Sp1 and Sp3 to
the T-allele of rs143383. RNAi-mediated silencing of Sp1 and Sp3
signiﬁcantly increased the expression of GDF5, and modulated the AEI
observed. Furthermore, results from ChIP revealed that these two
factors bind GDF5 in-vivo.
Conclusions: p15, Sp1 and Sp3 bind to GDF5, this binding is modulated
by genotype at the rs143383 SNP, and these factors differentially
regulate the expression of GDF5. Now that these trans-acting factors
have been identiﬁed, they can serve as targets for modulating the OA
genetic deﬁcit mediated by rs143383.
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BRAIN FUNCTIONAL PROPERTIES PREDICT PLACEBO ANALGESIA IN
KNEE OSTEOARTHRITIS
A. Mansour, M. Baliki, T.J. Schnitzer, A.V. Apkarian. Northwestern Univ.,
Chicago, IL, USA
Purpose: Chronic pain is the primary complaint associated with OA,
serving as a predictor of physical dysfunction and muscular weakness.
As blinded, randomized placebo-controlled trials of therapeutic agents
in OA have repeatedly demonstrated a marked reduction in pain
response to placebo, studies of the brain response to placebo may
inform on brain properites of OA itself. Although mechanisms of
placebo response have been repeatedly studied in humans, we are the
ﬁrst to investigate its underlying brain properties in a clinical drug
study design. Here we investigate the possibility of identifying brain
properties that predispose different OA patients to placebo analgesia.
Methods: 20 patients meeting ACR criteria for knee OA were enrolled
into this single-blinded 4 week study. At baseline, patients were
instructed that they might be receiving either active drug or placebo;
however they all were given placebo for 2 weeks after which the treat-
mentwas stopped. At baseline and at the end of the 2weeks the patients
underwent an fMRI brain scan as well as a structural high resolution T1
brain scan; efﬁcacy reportswere collected on both occasions. Twoweeks
post cessation of medication patients were contacted again and same
efﬁcacy reports were recollected. The primary efﬁcacy measure was
Visual Analogue Scale 24 hour average pain rating. Secondary efﬁcacy
measures included WOMAC Index; Pain detect, Beck depression Index
(BDI), and Pain catastrophizing scale (PCS). In addition, 17 healthy age-
and gender-matched participants without knee pain were scanned at
baseline to serve as controls. For the analysis, the patient groups were
stratiﬁed as responders vs. non-responders to the placebo treatment
based on a decrease in visual analogue scale (VAS) pain rating equal to or
greater than 20% from baseline. Analysis was then conducted to deter-
mine differences in brain fMRI data between OA patients and controls as
well as betweenOAplacebo-responders vs.OAplacebo-non-responders.
Results: Of the 20 patients enrolled, 9 weremale and 11 female; mean
age was 57.8±6.6 years; mean duration of OA was 12.1±10.0 years.
3 patients discontinued prior to their week 2 visit; of the remainder,
8 responded to placebo (mean VAS dropped from 72.514.1 to
32.520.5, i.e., 56% decrease in VAS) whilst 9 did not show any signiﬁ-
cant change in reported pain (VAS changed from 66.78.2 to 704.7, i.e.,
a mean increase of 7%). OA vs controls: By comparing the general number
of connections across all brain regions between OA patients and controls
we conclude that the region constituted by the medial prefrontal cortex
(mpfc) and nucleus accumbans as well as the caudate is more connected
(p <0.05, corrected for multiplicity) in patients with OA than in controls.
OA-responders vs. OA-non responders: The secondary somatosensorycortex (S2) was generally more linked in the OA non-responders (p-
corrected < 0.05). In this group, the S2 region displayed signiﬁcantly
more connectivity with the ventro-lateral prefrontal cortex (vlpfc).
Moreover, the vlpfc showedmore connectivity (p-corrected< 0.05) with
the part of the brain network identiﬁed for OA, namely mpfc. Both S2
counts and vlpfc-mpfc connectivity predicted with very high accuracy
(AUC¼. 97 and .96, respectively) responders to placebo.
Conclusions: In this study, we have shown that brain information
sharing (functional connectivity) is different in OA in contrast to healthy
control subjects. Furthermore, analysis of activity of components of this
network predicts the response to placebo. Thus, placebo analgesia is
predictable from brain connectivity (information shared between brain
regions), prior to start of the placebo treatment trial. These results
suggest that distinct sub-groups of OA have distinct propensities for
placebo based on their brain states. The speciﬁc characteristics that
distinguish between these groups remains to be identiﬁed. The results
of the present study have important implications regarding OA, clinical
trials in OA, and for future designs of treatments for OA.
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PAIN PERCEPTION IN HAND OSTEOARTHRITIS: RELATION BETWEEN
CLINICAL NODES, RADIOLOGICAL SEVERITY, PAIN THRESHOLD AND
BRAIN PAIN PROCESSING
N.Sofat, J.Wajed, C. Smee,M.Hermansson, F.Howe, T.R. Barrick.StGeorge's,
Univ. of London, London, United Kingdom
Purpose: Hand osteoarthritis (OA) is a prevalent condition for which
treatments are based on analgesia and physical therapies. However, the
majority of patients continue to have symptoms of pain and reduced
function despite optimisation of current available treatments. We
hypothesised that inﬂammation in the hand joints due to osteoarthritis
enhances sensitivity and ﬁring of peripheral nociceptors, thereby
causing chronic pain. Our primary objective was to evaluate pain
perception in a cohort of participants with hand OA by assessing the
characteristics of nodal involvement, pain threshold in each hand joint
and radiological severity. Our secondary objective was to assess if
a standardised painful hand task showed evidence of brain pain pro-
cessing pathways using functional brain neuroimaging.
Methods: Participants with proximal and distal interphalangeal (PIP
and DIP) joint hand OA and non-OA controls were recruited. Clinical
parameters of local joint disease including clinical nodes, VAS (visual
analog score) for pain (0-100 mm scale), HAQ (health assessment
questionnaire), Kellgren-Lawrence scores for radiological severity in
each hand joint (30 regions per hand/subject using standard hand
radiographs and pain thresholds performed with algometers (Wagner
Instruments, USA) over each joint were assessed. Central brain pain
processing in all participants in the cohort was then evaluated using
a standardised ﬁnger ﬂexion-extension task. Subjects underwent
functional brain neuroimaging in a 1.5 Tesla MRI scanner (GE Health-
care) whilst they performed the ﬁnger ﬂexion-extension task to
measure central components of pain processing. Activation of central
pain processing pathways was then evaluated using group analyses
with FMRIB software (www.fmrib.ox.ac.uk/fsl).
Results: All hand OA participants reported pain despite 92% taking oral
analgesic drugs. The mean VAS in hand OA participants was 59.31 mm
+/-8.19 compared with 4.00 mm +/- 1.89 in the control group. Hand OA
participants also had HAQ scores 8-fold higher than controls indicating
high levels of functional impairment (p<0.05).Objectivemeasuresof pain
using algometers on 780 joints in total demonstrated lower pain thresh-
olds across not only DIP and PIP, but also CMC,MCP andwrist joints in the
OAgroupversus controls (p<0.0001). Therewasaglobal reduction inpain
threshold in thehandOAgroupdespite themain radiological changes and
nodal disease being found in the PIP and DIP joints respectively. Pain
threshold in the OA group did not vary signiﬁcantly with increasing
radiological severity. Functional brain MRI during the painful ﬁnger
ﬂexion-extension task demonstrated increased activation of the thal-
amus, cingulate gyrus, frontal and somatosensory cortex in the hand OA
group that was not observed in the control group (p<0.05). The activated
brain regions we observed are known brain pain processing regions.
Conclusions: Our data demonstrate that hand OA subjects are sensi-
tised to pain due to increased ﬁring of peripheral nociceptors. Hand OA
subjects demonstrate lower pain thresholds globally in their hands
compared with controls and have enhanced central sensitisation as
demonstrated by increased activation of central brain pain processing
pathways. Our ﬁndings also suggest that pain processing in OA is
